The WSJ Venture Capital Dispatch today discusses the strategy by a few biotech's to pursue bio-betters instead of biosimilars. Companies like Femta Pharmaceuticals, Itero Biopharmaceuticals and Polytherics Ltd are choosing to go after the bio-better targets in an effort to boost value and reduce risk. Even though bio-betters will require more extensive clinical trials, the thought is that the pursuit of a bio-better will occur in a proven therapeutic area and will therefore be less risky form of new drug development given the experience gained from the initial drugs licensed. By definition, the bio-better will have clear advantages over the original therapy (otherwise it would be a "me-too") - like enhanced safety, efficacy or better dosing convenience.
It remains to be seen how this strategy will work, but for now these 3 companies have venture capital investors who are willing to back their ideas.
Posted by Bruce Lehr August 11th 2010.